Biogen's new CEO on the company's challenges ahead; the latest C-suite departures in pharma

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by     STAT+: Biogen's new CEO, clear-eyed about company's challenges, prepares to take the reins By Matthew Herper and Adam Feuerstein and Jason Mast Photo illustration: STAT Christopher Viehbacher knows running Biogen may be one of the toughest jobs in the pharmaceutical industry, but is eager for the opportunity. Read More STAT+: Unexpected troubles hit large medical billing firm R1 RCM, part-owned by Ascension By Bob Herman Adobe The stock price of R1 RCM tanked by roughly 50% this week after the medical billing company reported an unexpected $30 million loss. Read More STAT+: Up and down the ladder: The latest comings and goings By Ed Silverman Alex Hogan/STAT From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. Read More Sponsored Insight by FISHAWACK HEALTH Report: Key considerations for launching cell and gene therapies Drug developers are facing a steeper climb to commercialization filled with challenges and opportunities as cell and gene therapies induce a paradigm shift in the manufacture and development of pharmaceutical products. In our new report we reveal expert-led analysis of the trends shaping the commercialization of novel cell and gene therapies, advice on the changing policy and regulatory landscape, an interview on AstraZeneca's cell therapy pipeline for chronic diseases, and patient insights. Access the report now. STAT+: Head of MassBio trade group is out after serving just over a year By Jonathan Saltzman — Boston Globe Jessica Rinaldi/The Boston Globe Barely a year after he was named head of the Massachusetts Biotechnology Council, former state Senator Joseph Boncore has been ousted. Read More Friday, November 11, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser